Abstract:Abstract PTEN is an important tumor suppressor that plays an essential role in regulating cell proliferation. Loss of PTEN function is implicated in approximately 50% of metastatic cancers. Individuals with pathogenic PTEN variants are at significantly elevated risk of developing hereditary cancer syndromes such as PTEN hamartoma tumor syndrome. While genetic testing for PTEN is valuable for identifying individuals at risk, 47% of 3065 publicly reported PTEN variants are not conclusively classified; they either have conflicting interpretations of pathogenicity or are labeled as “Variants of Uncertain Significance (VUS)” and are not clinically actionable. The lack of a clear interpretation for these PTEN variants hinders the targeted care and surveillance of patients and places a strain on the healthcare system. To overcome this issue, our aim is to develop a clinically relevant tool for assessing the pathogenic effects of PTEN variants.We hypothesize that loss of function (LoF) PTEN variants will lead to changes in cellular phenotypic profiles that can be measured through single-cell phenotypic profiling. Thus, our goal is to investigate the functional status of exogenously expressed PTEN variants in PTEN-/- HEK 293 cells. We developed a multiplexed high content imaging assay to characterize PTEN and its key signaling partners such as phospho-Akt. Additionally, we developed a deep learning based single-cell phenotypic profiling pipeline named Paracell that uses subcellular segmentation to extract 540 phenotypic features. Cells that exhibit abnormal phenotypic profiles are indicative of loss of PTEN function. Preliminary results from testing 73 missense variants of PTEN showed that functional and LoF PTEN variants form distinctive clusters in a two-dimensional UMAP plot based on Paracell outputs, suggesting that our approach can identify potentially pathogenic variants of PTEN.Through characterizing novel VUS, we can elucidate structural domains involved in PTEN’s tumor suppressing activity. The result of these classifications will enable more optimized detection, diagnosis, and surveillance strategies for PTEN-related cancers. Ultimately, we aim to contribute to improving the genetic testing of PTEN and the development of targeted therapies. Citation Format: Ajay P. Singh, Jasmine Wen, David Nguyen, Vedanta Khan, Kiran Dhami, Kaitlynn Meier-Ross, Benjamin Martin, Jesse T. Chao. Characterizing variants of uncertain significance in the tumor suppressor gene known as phosphatase and tensin homolog (PTEN) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6233.

A robust immunohistochemical assay for detecting PTEN expression in human tumors

The Clinical Significance of PTEN Protein Expression in Colorectal Carcinoma

Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies

Regulation of the tumor suppressor PTEN by natural anticancer compounds

Comparison of immunohistochemistry and next-generation sequencing results in oncogenic PTEN missense mutations

Phosphatase and Tensin Homolog (PTEN) Expression as a Surrogate Biomarker Correlated With the Depth of Invasion in Cutaneous Malignant Melanoma

Utilizing PTEN immunohistochemistry as a screening test for Cowden syndrome

Abstract 6233: Characterizing variants of uncertain significance in the tumor suppressor gene known as phosphatase and tensin homolog (PTEN)

Preparation and characterization of a polyclonal antibody against PTEN-Long

[Possibility of PTEN Expression on Predicting Pathologic Risk Factors of Endometrioid Adenocarcinoma Before Operation].

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients

High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trial

PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival

The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer

Expression of PPARγ and PTEN in Human Colorectal Cancer: an Immunohistochemical Study Using Tissue Microarray Methodology.

Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers

The usefulness of evaluating PTEN expression for accurate grading of phyllodes tumors

Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (Qpten).

The Critical Role of PTEN Mutation in Cellular Process and Drug Selection of Endometrial Cancer

PTEN-related risk classification models for predicting prognosis and immunotherapy response of hepatocellular carcinoma

Clinical significance of tumor suppressor PTEN in colorectal carcinoma